Lista de obras -

A mouse model of uterine leiomyosarcoma

artículo científico publicado en 2004

A mouse plasma peptide atlas as a resource for disease proteomics

artículo científico publicado en 2008

Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.

artículo científico publicado en 2014

Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma

artículo científico publicado en 2015

Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non-Small Cell Lung Cancer.

artículo científico publicado en 2018

DOK2 inhibits EGFR-mutated lung adenocarcinoma

artículo científico publicado en 2013

De novo selection of oncogenes

scientific article published on 16 December 2013

Defective insulin secretion in pancreatic beta cells lacking type 1 IGF receptor

artículo científico publicado en 2002

Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors

artículo científico publicado en 2007

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

artículo científico publicado en 2004

EGFR Mutations in Non-Small-Cell Lung Cancer: Find, Divide, and Conquer

artículo científico publicado en 2015

ERBB3-independent activation of the PI3K pathway in EGFR-mutant lung adenocarcinomas

artículo científico publicado en 2015

Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA.

artículo científico publicado en 2018

Early shear stress signaling on vascular endothelium by a modified partial carotid ligation model

artículo científico publicado en 2011

Emerging Agents and New Mutations in EGFR-Mutant Lung Cancer

artículo científico publicado en 2015

Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma

artículo científico publicado en 2009

Expression of ERp29, an endoplasmic reticulum secretion factor in basal-cell carcinoma

artículo científico publicado en 2006

Expression of p21waf1/Cip1 in stromal fibroblasts of primary breast tumors

artículo científico publicado en 2008

Generation of drug-resistant tumors using intermittent dosing of tyrosine kinase inhibitors in mouse

artículo científico publicado en 2014

Genome-Wide RNA Interference: Functional Genomics in the Postgenomics Era.

artículo científico publicado en 2017

HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation

artículo científico publicado en 2012

How Genetically Engineered Mouse Tumor Models Provide Insights Into Human Cancers ⬇️

artículo científico publicado el 24 de enero de 2011

Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer

artículo científico publicado en 2017

Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines

artículo científico publicado en 2017

Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas

artículo científico publicado en 2007

Isolation of epithelial, endothelial, and immune cells from lungs of transgenic mice with oncogene-induced lung adenocarcinomas

artículo científico publicado en 2015

Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor-Driven Lung Adenocarcinoma

artículo científico publicado en 2015

Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors

artículo científico publicado en 2006

Lung cancer in the era of precision medicine

artículo científico publicado en 2015

Lung cancer signatures in plasma based on proteome profiling of mouse tumor models

artículo científico publicado en 2011

MYCxing it up with FGFR1 in squamous cell lung cancer

artículo científico publicado en 2014

Modulation of notch signaling elicits signature tumors and inhibits hras1-induced oncogenesis in the mouse mammary epithelium

artículo científico publicado en 2004

Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma

artículo científico publicado en 2016

Myc is a Notch1 transcriptional target and a requisite for Notch1-induced mammary tumorigenesis in mice

artículo científico publicado en 2006

Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance

artículo científico publicado en 2013

Noncovalent wild-type-sparing inhibitors of EGFR T790M

artículo científico publicado en 2012

Notch in mammary gland development and breast cancer

artículo científico publicado en 2004

Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced by Myc and mutant Kras

artículo científico publicado en 2008

Oncogenic EGFR Represses the TET1 DNA Demethylase to Induce Silencing of Tumor Suppressors in Cancer Cells

artículo científico publicado en 2016

Optimizing the sequence of anti-EGFR-targeted therapy in EGFR-mutant lung cancer

artículo científico publicado en 2014

PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause?

artículo científico publicado en 2016

Perfect ALKemy: optimizing the use of ALK-directed therapies in lung cancer

artículo científico publicado en 2014

Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer

artículo científico publicado en 2014

The Impact of Smoking and TP53 mutations in lung adenocarcinoma patients with targetable mutations - the Lung Cancer Mutation Consortium (LCMC2).

artículo científico publicado en 2017

The Next Wave of EGFR Tyrosine Kinase Inhibitors Enter the Clinic

artículo científico publicado en 2015

Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells

artículo científico publicado en 2017

Transcriptomic Hallmarks of Tumor Plasticity and Stromal Interactions in Brain Metastasis.

artículo científico publicado en 2019

Translational therapeutics in genetically engineered mouse models of cancer

artículo científico

Two Sides of the Same Coin: EGFR Exon 19 Deletions and Insertions in Lung Cancer ⬇️

artículo científico publicado el 8 de febrero de 2012

YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics.

artículo científico publicado en 2018

Lista de obras de

A mouse model of uterine leiomyosarcoma

A mouse plasma peptide atlas as a resource for disease proteomics

Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.

Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma

Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non-Small Cell Lung Cancer.

DOK2 inhibits EGFR-mutated lung adenocarcinoma

De novo selection of oncogenes

Defective insulin secretion in pancreatic beta cells lacking type 1 IGF receptor

Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

EGFR Mutations in Non-Small-Cell Lung Cancer: Find, Divide, and Conquer

ERBB3-independent activation of the PI3K pathway in EGFR-mutant lung adenocarcinomas

Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA.

Early shear stress signaling on vascular endothelium by a modified partial carotid ligation model

Emerging Agents and New Mutations in EGFR-Mutant Lung Cancer

Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma

Expression of ERp29, an endoplasmic reticulum secretion factor in basal-cell carcinoma

Expression of p21waf1/Cip1 in stromal fibroblasts of primary breast tumors

Generation of drug-resistant tumors using intermittent dosing of tyrosine kinase inhibitors in mouse

Genome-Wide RNA Interference: Functional Genomics in the Postgenomics Era.

HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation

How Genetically Engineered Mouse Tumor Models Provide Insights Into Human Cancers ⬇️

Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer

Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines

Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas

Isolation of epithelial, endothelial, and immune cells from lungs of transgenic mice with oncogene-induced lung adenocarcinomas

Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor-Driven Lung Adenocarcinoma

Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors

Lung cancer in the era of precision medicine

Lung cancer signatures in plasma based on proteome profiling of mouse tumor models

MYCxing it up with FGFR1 in squamous cell lung cancer

Modulation of notch signaling elicits signature tumors and inhibits hras1-induced oncogenesis in the mouse mammary epithelium

Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma

Myc is a Notch1 transcriptional target and a requisite for Notch1-induced mammary tumorigenesis in mice

Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance

Noncovalent wild-type-sparing inhibitors of EGFR T790M

Notch in mammary gland development and breast cancer

Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced by Myc and mutant Kras

Oncogenic EGFR Represses the TET1 DNA Demethylase to Induce Silencing of Tumor Suppressors in Cancer Cells

Optimizing the sequence of anti-EGFR-targeted therapy in EGFR-mutant lung cancer

PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause?

Perfect ALKemy: optimizing the use of ALK-directed therapies in lung cancer

Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer

The Impact of Smoking and TP53 mutations in lung adenocarcinoma patients with targetable mutations - the Lung Cancer Mutation Consortium (LCMC2).

The Next Wave of EGFR Tyrosine Kinase Inhibitors Enter the Clinic

Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells

Transcriptomic Hallmarks of Tumor Plasticity and Stromal Interactions in Brain Metastasis.

Translational therapeutics in genetically engineered mouse models of cancer

Two Sides of the Same Coin: EGFR Exon 19 Deletions and Insertions in Lung Cancer ⬇️

YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics.